However, the success of this strategy relies on patient stratification based on their CIN levels, and the co-existence of gene alterations (e.g., TP53 or PIK3CA) that can reduce the toxicity of elevated CIN. Here, TP53 is linked to cervical squamous intraepithelial neoplasia.